Zoeken naar een onderzoek

The safety and cost-effectiveness of discontinuing disease-modifying therapies in relapsing-onset multiple sclerosis (DOT-MS): a randomized rater-blinded multicenter trial.

Discontinuation of first-line disease modifying medication (DMT) in patients with relapsing-onset multiple sclerosis that are inflammatory stable for at least 5 years, can be safely done without the return of inflammatory activity.

The Value of Contract Based Care for Patients with Diabetes Mellitus on Insulin Pump Therapy

Signing a contract will result in more adequate use of insulin pump therapy, resulting in better diabetes regulation

Influences of a surgical intervention on the quality of life of children with uveitis

Both surgical interventions have impact on the quality of life